


Pemirolast potassium

Cat. No.:	HY-B0538A
CAS No.:	100299-08-9
Molecular Formula:	C ₁₀ H ₇ KN ₆ O
Molecular Weight:	266.3
Target:	Histamine Receptor
Pathway:	GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 50 mg/mL (187.76 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	3.7552 mL	18.7758 mL	37.5516 mL
				5 mM	0.7510 mL	3.7552 mL	7.5103 mL
				10 mM	0.3755 mL	1.8776 mL	3.7552 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (375.52 mM); Clear solution; Need ultrasonic						

BIOLOGICAL ACTIVITY

Description	<p>Pemirolast potassium (TWT-8152) is a histamine H1 antagonist and mast cell stabilizer that acts as an antiallergic agent. Target: Histamine H1 Receptor. Pemirolast potassium (TWT-8152) is a new oral, nonbronchodilator antiallergy medication that is being evaluated for the therapy of asthma [1]. Pemirolast potassium (TWT-8152) inhibits chemical mediator release from tissue mast cells and is also shown to inhibit the release of peptides including substance P, Pemirolast potassium (TWT-8152) reduces kaolin intake by inhibition of substance P release in rats [2]. Pemirolast potassium (TWT-8152) potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats [3]. Pemirolast potassium (TWT-8152) potassium is used for the treatment of allergic conjunctivitis and prophylaxis for pulmonary hypersensitivity reactions to drugs such as paclitaxel [4].</p>
-------------	---

REFERENCES

[1]. Kemp, J.P., et al., Pemirolast, a new oral nonbronchodilator drug for chronic asthma. *Ann Allergy*, 1992, 68(6): p. 488-91.

[2]. Tatsushima, Y., et al., Pemirolast reduces cisplatin-induced kaolin intake in rats. Eur J Pharmacol, 2011. 661(1-3): p. 57-62.

[3]. Itoh, Y., et al., Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats. Neuropharmacology, 2004. 46(6): p. 888-94.

[4]. Abelson, M.B., et al., Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies. J Ocul Pharmacol Ther, 2002

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA